Target Discovery & Validation Products

Target discovery and validation is a foundational stage of drug development, in which researchers identify genes, proteins, or pathways implicated in disease and confirm their functional relevance before committing resources to lead compound development. This process directly influences downstream success rates, as targets that are poorly validated often contribute to costly late-stage clinical failures.

Target discovery typically begins with genomic, transcriptomic, or proteomic profiling to identify candidate genes or proteins that are differentially expressed or genetically associated with a disease phenotype. Identified candidates are further assessed by methods such as selective knockout or modulation of target expression to observe the resulting phenotypic or functional consequences. Validation is further supported through orthogonal approaches, including expression analysis by qPCR or RT-PCR, protein-level confirmation, and spatial localization. Together, these methods build a weight-of-evidence case for a target's disease relevance before it advances toward assay development and screening. Product categories that support target discovery and validation efforts are highlighted below:

Essential Tools and Techniques

• Next generation sequencing (NGS) enables genome-wide identification of disease-associated variants and expression patterns. NGS library preparation and sample prep kits, along with RNA-Seq and single cell sequencing kits, allow researchers to resolve target expression at both bulk and single-cell resolution, while NGS services offer an outsourced route for labs without in-house sequencing infrastructure.
• Epigenetics tools, including ChIP-Seq kits and bisulfite sequencing (Methyl-Seq) kits, are increasingly used to characterize regulatory mechanisms, such as histone modification and DNA methylation, that influence target gene expression independent of underlying sequence changes.
• CRISPR products, such as CRISPR-Cas9 and guide RNA reagents, Cas9 nuclease, and CRISPR knockout kits, are widely used to functionally validate candidate targets by directly perturbing gene expression in cellular models. Transfection kits and reagents support efficient delivery of these editing components, while gene editing services offer a contracted alternative for more complex constructs.
• Expression analysis tools, including qPCR, RT-PCR, and microarrays, allow researchers to quantify target transcript abundance across experimental conditions. RNA amplification kits and cDNA clones or libraries further support downstream cloning and functional studies once a target of interest has been identified.
• Protein expression and purification tools, including cloning and expression kits, in vitro transcription/translation systems, antibody purification kits (Protein A, Protein G, and Protein A/G formats), and protein extraction and fractionation kits, enable researchers to produce and isolate candidate proteins in a form suitable for downstream functional and structural characterization.
• Proteomics tools, such as mass spectrometry and protein arrays, offer high-throughput, unbiased approaches to confirm target identity and quantify protein expression across complex sample sets, often serving as a complementary validation step alongside antibody-based methods.
• Spatial biology platforms, along with immunohistochemistry and in situ hybridization techniques, allow researchers to confirm target expression within its native tissue architecture, an important consideration given that expression observed in bulk assays does not always reflect the cellular or spatial context relevant to disease pathology.

Prospective buyers should consider how these tools integrate across the discovery-to-validation continuum, as no single technique offers definitive proof of target relevance. A combination of genomic, functional, and spatial validation approaches remains the most reliable strategy for building confidence in a candidate target before advancing it into the drug development pipeline.